Forxiga

Forxiga is a prescription medication used primarily for the treatment of type 2 diabetes mellitus. It contains the active ingredient dapagliflozin, which is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. By inhibiting the SGLT2 protein in the kidneys, dapagliflozin reduces glucose reabsorption, leading to increased glucose excretion in the urine and thereby lowering blood glucose levels. (en.wikipedia.org)

The drug was developed by Bristol-Myers Squibb, an American pharmaceutical company known for its focus on innovative medicines. (news.bms.com) In 2012, Forxiga was approved by the European Medicines Agency (EMA) for the treatment of type 2 diabetes. (de.wikipedia.org)

In 2013, AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company, acquired the rights to Forxiga. AstraZeneca is headquartered in Cambridge, UK, and is recognized for its global presence in the pharmaceutical industry. (de.wikipedia.org)

Forxiga is manufactured in multiple countries, including the United States and the United Kingdom, reflecting AstraZeneca's extensive global manufacturing capabilities. The drug is available in various forms, including 5 mg and 10 mg tablets, and is distributed worldwide to manage type 2 diabetes effectively. (ozmd.org)

In summary, Forxiga is a globally recognized antidiabetic medication developed by Bristol-Myers Squibb and now owned by AstraZeneca, with manufacturing facilities in multiple countries to meet the worldwide demand for type 2 diabetes treatment.